Fungi · Scientific monograph
Hericium erinaceus
Lion's Mane / Pom Pom Mushroom
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Neurological & Cognitive Research, Cognitive Function Research
Research overview
Historical use
Used in Traditional Chinese and Japanese medicine for centuries primarily to treat gastrointestinal disorders (gastric ulcers, chronic gastritis) and as a general tonic. Known in Japan as 'Yamabushitake'. Referenced in historical texts as a food and medicine for digestive health.
Modern research context
Clinically studied for its nerve growth factor (NGF)-stimulating properties. A 2009 double-blind RCT demonstrated significant improvement in mild cognitive impairment after 16 weeks of supplementation [1]. A 4-week pilot study documented reduction in depression and anxiety scores [4]. Neuroprotective mechanisms include antioxidant and anti-inflammatory activity mediated by hericenones and erinacines [2][3]. Evidence supports investigation as a neuroprotective agent in Alzheimer's and Parkinson's disease models [2][3].
Adverse effects
Generally well-tolerated. Reported adverse effects include mild GI discomfort (nausea, bloating), and rare allergic reactions including contact dermatitis and respiratory allergy in sensitised individuals.
Contraindications
Known allergy to Hericium species or other mushrooms. Caution with anticoagulants due to potential platelet inhibition. Caution in autoimmune conditions given immunomodulatory properties.
Clinical and phytochemical data
Used part
Fruiting body (hericenones) and mycelium (erinacines)
Primary active compounds
Hericenones A–H (cyathane diterpenoids, fruiting body)
Erinacines A–K (cyathane diterpenoids, mycelium)
Beta-glucans
Ergosterol
Mechanism of action
Hericenones and erinacines stimulate de novo synthesis and secretion of NGF (nerve growth factor) in astrocytes, promoting neuronal survival and axonal growth. Erinacines cross the blood-brain barrier (demonstrated in rodent studies) via passive diffusion. Anti-neuroinflammatory effects via inhibition of MAPK and NF-κB pathways. Promotes hippocampal neurogenesis via TrkA/Erk1/2 signalling.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Erinacine A crosses the blood-brain barrier in rodents; human CNS penetration not directly measured. Hericenone bioavailability in humans is not well characterised.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Erinacine A distributes into CNS tissue in rodent models, including the hippocampus and cortex. Hericenones are lipophilic and expected to distribute into lipid-rich tissues. No human plasma protein binding or tissue distribution data are available.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Limited human data. Hepatic phase I/II metabolism assumed based on compound structure.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Limited human data. Presumed renal and biliary excretion of metabolites.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 >5 g/kg (oral, mice). No organ toxicity identified in 28-day subacute studies in rodents. Human clinical trials up to 3 g/day for 16 weeks showed no significant adverse effects.
Special precautions
Pregnancy
Insufficient human clinical data. No animal teratogenicity studies identified. Avoid due to lack of safety evidence.
Lactation
Excretion in human breast milk unknown. Avoid during breastfeeding.
Hepatic impairment
No hepatotoxicity reported in literature. No dose adjustment studies available; use with standard monitoring.
Renal impairment
No specific contraindication identified. Limited data in renal impairment populations.
Sources and references
- [1] - Mori K., "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.", Phytother Res, 2009, PMID: 18844328
- [2] - Contato AG., "Lion's Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential-A Narrative Review.", Nutrients, 2025, PMID: 40284172
- [3] - Chong PS., "Therapeutic Potential of Hericium erinaceus for Depressive Disorder.", Int J Mol Sci, 2019, PMID: 31881712
- [4] - Nagano M., "Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake.", Biomed Res, 2010, PMID: 20834180
- [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265